Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:3/26/2009

cash, cash equivalents and marketable securities as of December 31, 2008 were $25.9 million, excluding restricted cash of $1.9 million. As previously disclosed, Jazz Pharmaceuticals did not make the $4.5 million interest payment due on December 31, 2008 on its outstanding $119.5 million principal amount of senior secured notes, and has received a notice of default from the noteholders. As a result of the default, the noteholders have the right, at any time, to accelerate the notes and require payment in full of the principal and interest, plus a pre-payment penalty. While Jazz Pharmaceuticals believes that its current cash resources, together with anticipated revenues from product sales, will be sufficient to fund its operations, they are not sufficient to fund both its operations and any payment of interest or repayment of principal on the notes. Jazz Pharmaceuticals is currently seeking a number of financing and strategic alternatives and is in discussions with the holders of the senior secured notes with respect to the December 31, 2008 interest payment default and the status of the notes. The report of the Jazz Pharmaceutical's independent registered public accounting firm on the company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2008 includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release c
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... September 5, that its Private Label Jalapeno Bagels are ... small stones. Publix Jalapeno Bagels were sold ... bakery department. , Taking into consideration the latest ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- A test used to diagnose ... where certain lung infections are more common, a new analysis ... is through the use of what,s known as functional imaging. ... FDG-PET is used, according to the study authors. Cancerous ... parts of the lungs that don,t have cancer, according ...
(Date:9/23/2014)... September 23, 2014 Grinnell Mutual ... improvement projects in the Midwest. Working Together Making ... three non-profit organizations with projects positively impacting their ... rural marketplace make their communities a better places,” ... and Community Relations Barb Baker. “Their leadership—as coaches, ...
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... Texas (PRWEB) September 23, 2014 ... for allergic rhinitis (AR) is highly fragmented, ... different SIT formulations available, under different regulatory ... between markets. Europe has the most developed ... (SLIT), and allergen immunotherapy tablets (AITs) all ...
Breaking Medicine News(10 mins):Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2Health News:Note to young men: Fat doesn't pay 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... House ceremony next month, Thomas L. Kash, PhD, assistant professor ... for Alcohol Studies at the University of North Carolina at ... Career Award for Scientists and Engineers (PECASE). , This is ... science and engineering professionals in the early stages of their ...
... in the October 2011 issue of The FASEB ... "healthy" ingredient in red wine, stops breast cancer cells ... This discovery, made by a team of American and ... is able to counteract the malignant progression since it ...
... By Serena Gordon HealthDay Reporter , WEDNESDAY, Sept. 28 ... advanced Alzheimer,s or other form of severe dementia will be shuttled ... months of life, a new U.S. study shows. The ... Depending on where a patient lives, as many as ...
... the British Journal of Sports Medicine * highlights the injury ... chance of a school player suffering an injury during a single ... research, could be as high as 90 per cent. The ... City University say there is an urgent need to inform children, ...
... with dementia can still make decisions in their everyday lives ... as their condition advances. This is one of the preliminary ... and Social Research Council (ESRC) into how married couples living ... study is investigating how couples make decisions over issues such ...
... dose of the hallucinogen psilocybin, the active ingredient in ... measureable personality change lasting at least a year in ... new study, according to the Johns Hopkins researchers who ... part of the personality known as openness, which includes ...
Cached Medicine News:Health News:UNC researcher to receive highest US honor for early career science professionals 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 2Health News:End-Stage Alzheimer's Patients Often Hospitalized Unnecessarily 3Health News:Academic issues warning on schoolboy rugby 2Health News:Living with dementia and making decisions 2Health News:Single dose of hallucinogen may create lasting personality change 2Health News:Single dose of hallucinogen may create lasting personality change 3
(Date:9/23/2014)... Research and Markets has announced ... Markets" report to their offering. ... - including products to treat cancer, diabetes, HIV/AIDS and ... the final stages of clinical drug testing for new ... production capital to upscale while anticipating FDA or EMA ...
(Date:9/23/2014)... -- SiteOne Therapeutics Inc. today announced the completion of its ... Management and Biobrit LLC, with additional investors Mission Bay ... financing positions SiteOne to advance its oral Na V ... its technology platform for long-acting local analgesics, pain diagnostics ... the financing, Lowell Sears (Sears Capital Management) ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... monitoring board (DSMB) has,recommended continuation of the company,s ... brief intravenous infusion of Viprinex(TM) (ancrod),started within 6 ... 3,months. This is the fifth DSMB meeting for ...
... Genmab has,announced that HuMax-EGFr (zalutumumab) inhibits epidermal ... factor receptor (EGFr),molecules into a very compact, ... central to its role in signaling, and ... of cancer cell growth., Genmab A/S ...
Cached Medicine Technology:Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod) 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 3
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Medicine Products: